LOJUXTA 5 mg, capsules 28 capsules
Active ingredients: Lomitapide, Lomitapide mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LOJUXTA 5 mg, gélules
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 28 gélule(s)
- Marketing authorisation holder
- CHIESI FARMACEUTICI
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Dec 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69851117CIP72762599CIP133400927625992Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LOMITAPIDEgélule | 5 mg · une gélule | FT |
| MÉSILATE DE LOMITAPIDEgélule | 5,69 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.